UK trial confirms validity of neonatal extracorporeal membrane oxygenation (ECMO)
This article was originally published in Clinica
Executive Summary
A collaborative UK trial has found that 68% of neonates receiving extracorporeal membrane oxygenation (ECMO) for severe but reversible respiratory failure survive. The 55 hospitals participating in a three-year nationwide randomised study of 185 infants found that this compares with a 41% survival rate following conventional care procedures, reports The Lancet (July 13th).